PMID- 38345715
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240310
IS  - 2198-6576 (Print)
IS  - 2198-6584 (Electronic)
IS  - 2198-6576 (Linking)
VI  - 11
IP  - 2
DP  - 2024 Apr
TI  - Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis 
      Treated with Upadacitinib: An Analysis from the CorEvitas Registry.
PG  - 363-380
LID - 10.1007/s40744-024-00639-4 [doi]
AB  - INTRODUCTION: Data assessing longer-term real-world effectiveness and treatment 
      patterns with upadacitinib (UPA), a Janus kinase inhibitor, in rheumatoid 
      arthritis (RA) are lacking. We assessed improvement in clinical and 
      patient-reported outcomes and treatment patterns for up to 12 months among adult 
      patients with RA initiating UPA. METHODS: Data were collected from the 
      CorEvitas((R)) RA Registry (08/2019-04/2022). Eligible patients had moderate to 
      severe RA (Clinical Disease Activity Index [CDAI] > 10) and follow-up visits at 6 
      or 12 months after UPA initiation. Outcomes were mean change from baseline, 
      percentage achieving minimal clinically important differences (MCID) in clinical 
      and patient-reported outcomes, and disease activity at follow-up. We evaluated 
      clinical outcomes and therapy changes among patients with tumor necrosis factor 
      inhibitor (TNFi) experience and among those receiving UPA as first-line therapy, 
      as well as those receiving UPA as monotherapy versus as part of combination 
      therapy. We further evaluated whether outcomes were similar among those that 
      remained on therapy. RESULTS: Patients treated with UPA (6-month cohort, N = 469; 
      12-month cohort, N = 263) had statistically significant improvements (p < 0.001) 
      in mean CDAI, tender/swollen joint counts, pain, and fatigue at follow-up. At 
      12 months, 46.0% achieved MCID in CDAI and 40.0% achieved low disease 
      activity/remission. Overall, 43.0% discontinued UPA at 12 months; of those 
      receiving combination treatment (N = 90) with conventional therapies and UPA, 
      42.2% (N = 38) discontinued conventional therapy. Findings were similar in the 
      6-month cohort and among subgroups. Changes from baseline and proportions of 
      patients achieving MCID or clinical outcomes tended to be numerically lower among 
      patients with TNFi experience and numerically higher among those receiving UPA as 
      first-line therapy. CONCLUSIONS: UPA initiation was associated with improvements 
      in clinical and patient-reported outcomes, with meaningful clinical improvements 
      regardless of prior TNFi experience, line of therapy, or concomitant use of 
      conventional therapies. Further research is needed to better understand sustained 
      response of UPA over longer treatment periods.
CI  - (c) 2024. The Author(s).
FAU - Baker, Joshua F
AU  - Baker JF
AUID- ORCID: 0000-0003-0799-7563
AD  - Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
AD  - Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
AD  - Department of Epidemiology and Biostatistics, University of Pennsylvania, 
      Philadelphia, PA, USA.
FAU - Zueger, Patrick
AU  - Zueger P
AUID- ORCID: 0000-0002-3412-9895
AD  - AbbVie, Inc, North Chicago, IL, USA. patrick.zueger@abbvie.com.
FAU - Ali, Mira
AU  - Ali M
AD  - AbbVie, Inc, North Chicago, IL, USA.
FAU - Bennett, Denise
AU  - Bennett D
AD  - CorEvitas, LLC, Waltham, MA, USA.
FAU - Yu, Miao
AU  - Yu M
AD  - CorEvitas, LLC, Waltham, MA, USA.
FAU - Munoz Maldonado, Yolanda
AU  - Munoz Maldonado Y
AUID- ORCID: 0000-0002-7607-9160
AD  - CorEvitas, LLC, Waltham, MA, USA.
FAU - McLean, Robert R
AU  - McLean RR
AUID- ORCID: 0000-0001-5352-3794
AD  - CorEvitas, LLC, Waltham, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20240212
PL  - England
TA  - Rheumatol Ther
JT  - Rheumatology and therapy
JID - 101674543
PMC - PMC10920593
OTO - NOTNLM
OT  - Patient-reported outcomes
OT  - Real-world evidence
OT  - Registry
OT  - Rheumatoid arthritis
OT  - Upadacitinib
COIS- Joshua F. Baker has received consulting fees from CorEvitas and Cumberland Pharma 
      and has received funding from Horizon Pharma. Denise Bennett, Miao Yu, Yolanda 
      Munoz Maldonado, and Robert R. McLean are employees of CorEvitas (previously 
      Corrona, LLC). Mira Ali and Patrick Zueger are employees of AbbVie Inc. and may 
      own stock.
EDAT- 2024/02/12 15:43
MHDA- 2024/02/12 15:44
PMCR- 2024/02/12
CRDT- 2024/02/12 11:12
PHST- 2023/08/09 00:00 [received]
PHST- 2024/01/12 00:00 [accepted]
PHST- 2024/02/12 15:44 [medline]
PHST- 2024/02/12 15:43 [pubmed]
PHST- 2024/02/12 11:12 [entrez]
PHST- 2024/02/12 00:00 [pmc-release]
AID - 10.1007/s40744-024-00639-4 [pii]
AID - 639 [pii]
AID - 10.1007/s40744-024-00639-4 [doi]
PST - ppublish
SO  - Rheumatol Ther. 2024 Apr;11(2):363-380. doi: 10.1007/s40744-024-00639-4. Epub 
      2024 Feb 12.